IDOV-Immune for Advanced Solid Tumors

Key Who May Qualify: - Age ≥ 18 years. - diagnosed by tissue sample (biopsy-confirmed) advanced solid tumors that have progressed despite standard therapy, or for which no standard therapy exists. - ECOG performance status ≤ 1. - tumors that can be measured on scans v1.1. - Adequate organ and bone marrow function. - At least 28 days since major surgery, prior immunotherapy, or radiotherapy (with exceptions for minor procedures). - Negative pregnancy test for women of childbearing potential. - Agreement to use effective contraception during treatment and for 3 months after. - Ability to provide willing to sign a consent form and comply with study requirements. Key Who Should NOT Join This Trial: - Prior treatment with an oncolytic virus. - Active or recent vaccinia virus infection or smallpox/monkeypox vaccination within 10 years. - Active uncontrolled infection requiring systemic treatment. - History of hepatitis B, hepatitis C, or HIV (unless meeting protocol-specific criteria). - Unresolved ≥ Grade 2 toxicities from prior therapies (except hair loss or stable chronic conditions). - Active or symptomatic autoimmune conditions (where your immune system attacks your own body) requiring systemic therapy. - Active or untreated cancer that has spread to the brain (unless stable per protocol). - Significant cardiac disease (e.g., NYHA Class III/IV heart failure). - Interstitial lung disease or prior pneumonitis requiring steroids. - Conditions requiring chronic immunosuppressive therapy. - Severe skin disorders or history of pancreatitis. - Bleeding disorders or history of recent serious thromboembolic events. - Any medical or psychiatric condition that could interfere with study participation. Always talk to your doctor about whether this trial is right for you.